Media Advisory - Oncolytics Biotech® Inc. to Present at RBC Capital Markets 2013 Healthcare Conference

Media Advisory - Oncolytics Biotech® Inc. to Present at RBC Capital Markets 
2013 Healthcare Conference 
CALGARY, Feb. 25, 2013 /CNW/ - Dr. Matt Coffey, Chief Operating Officer of 
Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present at the 2013 
RBC Capital Markets Healthcare Conference on Tuesday, February 26, 2013 at 
3:35 p.m. ET. The conference will take place on February 26(th) and 27(th) in 
New York, NY. 
A live audio link to the webcast presentation is available at: 
http://www.veracast.com/webcasts/rbc/healthcare2013/71114328.cfm or on the 
company's website at http://www.oncolyticsbiotech.com/presentations. It is 
recommended that listeners log on 10 minutes in advance of the presentation to 
register and download any necessary software. 
An audio replay will be accessible approximately one hour following the 
presentation on the Oncolytics website. 
About Oncolytics Biotech Inc. 
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials including a Phase III trial in head 
and neck cancers using REOLYSIN(®), its proprietary formulation of the human 
reovirus. For further information about Oncolytics, please visit: 
www.oncolyticsbiotech.com. 
The presentation and webcast times are subject to change. This release and the 
presentation related thereto contain forward-looking statements which involve 
known and unknown risks, delays, uncertainties and other factors not under the 
Company's control and which may cause actual results, performance or 
achievements of the Company to be materially different from the results, 
performance or expectations implied by these forward-looking statements. Such 
risks and uncertainties include, among others, the efficacy of REOLYSIN as a 
cancer treatment, the success and timely completion of clinical studies and 
trials, uncertainties related to the research and development of 
pharmaceuticals and uncertainties related to the regulatory process. Investors 
should consult the Company's quarterly and annual filings with the Canadian 
and U.S. securities commissions for additional information on risks and 
uncertainties relating to the forward-looking statements. Investors are 
cautioned against placing undue reliance on forward-looking statements. The 
Company does not undertake to update these forward-looking statements, except 
as required by applicable laws. 
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta, T2P 
3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@tmxequicom.com 
Dian Griesel, Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY 
10012 Tel: 212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com 
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/February2013/25/c8318.html 
CO: Oncolytics Biotech Inc.
ST: Alberta
NI: BTC CONF  
-0- Feb/25/2013 22:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.